Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioids: US Senate Committee Chairman's Discussion Drafts Broadly Reflect FDA Priorities

Mar 26 2018

• By Michael Cipriano

Opioid abuse epidemic concept

Related Content

Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns

Feb 14 2018

US FDA Proactively Exploring Hydexor Abuse Potential Ahead Of Ad Comm For Anti-Emetic/Opioid Combo

Feb 13 2018

Bipartisan Consensus Emerges To Let FDA Destroy Unlabeled Illicit Opioids

Mar 22 2018

New US FDA Powers On Rx Abuse Could Be 'Tailored' By Congress, Gottlieb Suggests

Mar 22 2018

Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

Dec 12 2017

FDA Expanding Opioid REMS To Immediate Release Formulations

Jul 11 2017

Proposed Legislation Would Help FDA Stop Illicit Opioids At Border -- And More

Mar 14 2018

Gottlieb Showing Capitol Hill Skills With Funding Success

Mar 24 2018

Related Companies

Charleston Laboratories, Inc.

Additional Topics

United States Legislation Risk Management Policy Neurology BioPharmaceutical

More from Legislation

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.